More than 15,000 people — firefighters, military veterans, and airport workers — are waiting for answers in one of the most consequential toxic exposure litigations in American history. The AFFF lawsuit docket inside MDL 2873 has reached a record 15,246 active personal injury claims as of August 2026, yet the landmark bellwether trial that was supposed to begin October 20, 2025 was quietly removed from the calendar. No replacement date has been set. Billions of dollars have already flowed to municipal water systems. Not one dollar of that money has reached an individual cancer patient. This article explains exactly where the litigation stands, what caused the delay, and how claimants can begin estimating their potential compensation right now.
What Is the AFFF Lawsuit and Who Is Affected?
Aqueous film-forming foam — commonly called AFFF — is a firefighting suppressant that was originally developed through a collaboration between the U.S. military and 3M, with the underlying chemistry patented as far back as 1965. For decades, AFFF was the standard tool for combating fuel fires at military installations, commercial airports, and training facilities across the country. The problem is that AFFF contains per- and polyfluoroalkyl substances, or PFAS — a class of synthetic compounds that do not break down in the human body or the environment, earning them the nickname “forever chemicals.”
The two most studied PFAS compounds in AFFF are PFOA and PFOS, both of which have been linked by scientific and regulatory bodies to a range of serious illnesses. The Centers for Disease Control and Prevention has identified occupational PFAS exposure as a significant public health concern, particularly for first responders. Recognized injury categories in MDL 2873 currently include kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and liver cancer. Research by the National Cancer Institute found a statistically significant association between PFAS exposure and testicular cancer specifically, while studies consistently show that firefighters carry triple the PFAS blood concentrations of the general population.
The defendants named across the AFFF lawsuit include some of the largest chemical and fire-safety manufacturers in the world: 3M, DuPont de Nemours, Chemours, Tyco Fire Products, Kidde-Fenwal, BASF, and others. The U.S. Department of Defense required military installations to stop using AFFF as of October 1, 2024, but the human damage from decades of prior exposure is only now fully emerging in courtrooms. A 2023 U.S. Geological Survey analysis estimated that as many as 45 percent of all U.S. tap water sources may contain detectable PFAS levels, underscoring just how widespread contamination has become.
The State of MDL 2873: A Record Docket Frozen at a Critical Moment
MDL 2873 was centralized in the U.S. District Court for the District of South Carolina in December 2018, beginning with just 75 cases before Judge Richard M. Gergel. By August 2026, that number has grown to 15,246 active personal injury claims — the highest caseload the docket has ever carried. The explosive growth is itself one reason the first personal injury bellwether trial was postponed: a surge in new filings in mid-2025 triggered additional administrative processing requirements that Judge Gergel addressed through a September 5, 2025 filing facilitation window, which ordered bundled complaints of up to 150 plaintiffs and standardized short-form complaints to manage the volume.
The bellwether trial that had been scheduled for October 20, 2025, was focused narrowly on personal injury claims against a small group of defendants. Its cancellation sent a ripple of uncertainty across the entire docket. No replacement trial date has been announced as of mid-2026, and the court continues to work through pre-trial motions, expert challenges, and case-management orders that must be resolved before any individual claim can be presented to a jury. Adding another layer of complexity, the Judicial Panel on Multidistrict Litigation declined in 2025 to expand the MDL to pull in turnout-gear-only cases, explicitly stating that such an expansion would be “a step too far towards an MDL unmoored from AFFF claims.” That boundary-setting decision has helped focus the court’s attention squarely on AFFF exposure claims, but it has also left firefighters whose injuries stem primarily from contaminated gear to pursue separate litigation tracks.
The sheer scale of MDL 2873 places it among the largest active mass tort dockets in the federal court system. Every motion practice ruling, every expert witness decision, and every scheduling order issued by Judge Gergel carries implications not just for the handful of cases immediately before the court but for all 15,246 claimants waiting behind them. That reality underscores why experienced mass tort counsel consistently advise clients to file early, preserve medical records, and remain patient — procedural complexity at this scale is measured in years, not months.
The Municipal Settlement Gap: Billions Paid Out — None to Cancer Patients
The financial settlements that have emerged from MDL 2873 so far have been substantial by any measure — but they have exclusively benefited municipal water systems and public utilities, not the individual firefighters and veterans at the heart of the personal injury litigation. The contrast is stark and, for many claimants, deeply frustrating.
3M reached a landmark settlement of up to $10.3 billion, payable over 13 years, to resolve claims from public water suppliers alleging that PFAS from AFFF contaminated drinking water sources nationwide. DuPont, Chemours, and Corteva collectively agreed to pay $1.185 billion to resolve similar water-system claims. Kidde-Fenwal, which filed for bankruptcy protection, established a $133 million settlement fund. These agreements resolved claims brought by cities, counties, and water authorities — entities with dedicated legal departments, expert environmental consultants, and the institutional resources to negotiate complex multi-party settlements.
Individual cancer patients have none of those advantages, and the personal injury track of MDL 2873 has moved on a fundamentally different timeline. As of mid-2026, there is still no global settlement covering personal injury and wrongful death claims. The most recent signal that defendants are engaging with the individual plaintiff population came when New Hampshire received a $4.68 million settlement payment from Tyco Fire Products and Chemguard in 2026 — a resolution addressing public water system PFAS and AFFF contamination in that state. While that payment went to a governmental entity rather than individual claimants, it demonstrates that defendants continue to resolve discrete pieces of the broader PFAS litigation puzzle. What remains missing is the comprehensive personal injury resolution that tens of thousands of firefighters, veterans, and airport workers are still waiting for.
AFFF Settlement Value: What Individual Claims Could Be Worth
Estimating the value of any individual AFFF claim before a global settlement framework exists is inherently speculative, but early case valuations and attorney projections provide a meaningful starting point for claimants trying to understand their potential compensation. Based on those projections, individual AFFF lawsuit settlements are currently estimated to range from approximately $20,000 to $600,000 or more, with the widest variation driven by the severity of the diagnosed condition, the duration and intensity of AFFF exposure, the claimant’s age and overall health profile, and the strength of the documentary evidence linking exposure to injury.
Claims involving terminal diagnoses — particularly aggressive kidney cancers or metastatic disease — tend to anchor the higher end of projected ranges. Wrongful death claims brought by surviving family members similarly project toward the upper end of valuations, reflecting both the economic losses associated with the death and the non-economic damages recognized in most jurisdictions. Claims involving conditions like thyroid disease or ulcerative colitis, while serious and recognized within the MDL, typically project toward lower settlement tiers because those conditions, while chronic, generally carry lower mortality risk and are more manageable with treatment.
Several factors beyond diagnosis influence individual claim value. The length of time a claimant worked with or around AFFF matters enormously — a career firefighter with 25 years of direct foam exposure presents a fundamentally different damages profile than a part-time airport worker with incidental contact. Medical documentation is equally critical: claimants who can demonstrate a clear diagnostic timeline, show continuous treatment records, and connect their occupational history to specific AFFF-using facilities will consistently achieve better outcomes than claimants whose evidence is fragmentary. Finally, the specific defendant or defendants named in a claim affects potential recovery, since different manufacturers and their insurers carry different settlement postures and financial capacities.
It bears repeating that these projections reflect attorney estimates and early valuations from analogous toxic tort litigations — they are not guaranteed outcomes. The absence of a global personal injury settlement as of mid-2026 means that actual compensation figures will not be confirmed until negotiations produce a framework, bellwether verdicts establish jury benchmarks, or both.
What Happens Next in the AFFF Litigation Timeline
The path forward in MDL 2873 runs through several critical procedural gates, each of which must clear before individual claimants can expect to see resolution. The most immediate is the rescheduling of the canceled bellwether trial. Judge Gergel has indicated that the court will return to trial-readiness preparation once outstanding pre-trial motions are resolved, but no firm date has been placed back on the calendar as of mid-2026. When a bellwether trial does occur, the verdict — whether for plaintiffs or defendants — will function as a critical data point for settlement negotiations across the entire docket.
Parallel to the trial track, the Plaintiffs’ Executive Committee and defense counsel are expected to continue exploring a global personal injury settlement framework. The municipal water settlement model — in which defendants pay into a structured fund distributed according to claim-specific criteria — is widely viewed as the most likely template for a personal injury resolution when it arrives. The $10.3 billion 3M water settlement demonstrated that defendants are capable of committing to large, structured payouts; the question is whether the personal injury litigation will develop the trial pressure necessary to bring defendants to the table at comparable scale.
Statute of limitations considerations remain urgent for anyone who has not yet filed. Most states apply a two-to-three year window from the date a claimant knew or reasonably should have known that their illness was linked to AFFF exposure. For individuals recently diagnosed with a covered condition, that clock is running now. Filing a lawsuit does not mean a claimant will go to trial — the overwhelming majority of MDL cases resolve through settlement — but it preserves legal rights that cannot be recovered once a deadline passes.
In the meantime, the continued growth of the MDL docket, now at 15,246 claims, signals that awareness of AFFF-related injuries is still spreading through the communities most affected. Advocacy organizations focused on firefighter health, veteran service organizations, and occupational health researchers continue to identify new populations of potentially affected individuals, and that ongoing outreach is expected to sustain filing activity through 2026 and into 2027.
Frequently Asked Questions About the AFFF Lawsuit in 2026
Why was the October 2025 AFFF bellwether trial canceled, and when will it be rescheduled?
The October 20, 2025 bellwether trial was removed from the calendar primarily because a surge in new case filings in mid-2025 required the court to implement new administrative procedures — including bundled complaints and standardized short-form filings — before trial preparation could responsibly resume. Outstanding expert witness challenges and pre-trial motion practice contributed to the delay as well. As of mid-2026, Judge Gergel has not announced a replacement trial date. Attorneys following the docket closely expect a new date to emerge once the court resolves the remaining pre-trial gatekeeping issues, but the timeline remains uncertain.
Who qualifies to file an AFFF lawsuit claim in 2026?
Individuals who may qualify include career and volunteer firefighters, military personnel who trained or worked at AFFF-using installations, airport firefighting and rescue personnel, and industrial workers with documented exposure to AFFF or PFAS-containing firefighting products. To have a viable personal injury claim, a claimant generally needs a diagnosis of one of the recognized injury categories — kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, liver cancer, or a related condition — and must be able to connect that diagnosis to a documented history of AFFF exposure. Family members of individuals who died from covered conditions may qualify to bring wrongful death claims. The specific eligibility standards continue to evolve as the MDL develops, making consultation with an experienced mass tort attorney the most reliable way to assess individual qualification.
Have any AFFF settlements paid money to individual cancer patients yet?
No. As of mid-2026, all significant AFFF settlement payments have gone to municipal water systems and public utilities — not to individual cancer patients or their families. The 3M, DuPont, and related water-system settlements resolved contamination claims brought by governmental entities. While settlements like the $4.68 million payment Tyco Fire Products and Chemguard made to New Hampshire in 2026 for public water system PFAS contamination demonstrate ongoing resolution activity, those funds flow to public entities, not individual claimants. There is still no global personal injury settlement in place, meaning that individual firefighters, veterans, and airport workers with AFFF-related cancers have not yet received compensation through the MDL process.
How much could an individual AFFF lawsuit settlement be worth?
Based on early case valuations and attorney projections, individual AFFF lawsuit settlements are currently estimated to range from approximately $20,000 to $600,000 or more. The wide range reflects significant variation in claim strength based on diagnosis severity, length and intensity of AFFF exposure, age, overall health, and the quality of documentary evidence. Terminal cancer diagnoses and wrongful death claims tend to project toward the higher end of the range, while claims involving less severe conditions typically project lower. These figures are projections, not guarantees, and actual settlement amounts will not be confirmed until a global personal injury framework is negotiated or bellwether verdicts establish jury benchmarks.
What should AFFF claimants do while waiting for the bellwether to be rescheduled?
The most important step for anyone who has not yet filed is to consult with a mass tort attorney immediately to assess whether a statute of limitations deadline is approaching. Filing a claim preserves legal rights regardless of how long the MDL process takes to reach resolution. Beyond filing, claimants should gather and organize all relevant medical records — including diagnosis dates, treatment histories, and physician notes — and compile documentation of their occupational history, including employment records, training logs, and any records identifying specific facilities or units where AFFF was used. Claimants who have already filed should maintain regular contact with their attorney and promptly respond to any requests for updated medical information or case-specific questionnaires, as the court’s ongoing administrative processes require current data from all active claimants.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.